Le-Zhen Ye, Jian-Xin Sun, Jing Chen, Jin-Liang Chen, Ye Bi, Yan-Ru Zhang
{"title":"Development and validation of an interpretable prediction model for high-grade vesicoureteral reflux in children with urinary tract infections.","authors":"Le-Zhen Ye, Jian-Xin Sun, Jing Chen, Jin-Liang Chen, Ye Bi, Yan-Ru Zhang","doi":"10.3389/fmed.2026.1864622","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>High-grade vesicoureteral reflux (VUR) is prone to causing adverse clinical outcomes such as kidney damage, recurrent urinary tract infections, and hypertension. Early identification of the risk of developing high-grade VUR in children with urinary tract infections is of great significance for reducing unnecessary voiding cystourethrography (VCUG), guiding clinical decisions, and optimizing antibiotic management strategies.</p><p><strong>Methods: </strong>A total of 434 children with urinary tract infections who completed VCUG examination were retrospectively enrolled in this study. They were randomly divided into a training set (<i>n</i> = 304) and a test set (<i>n</i> = 130) in a 7:3 ratio. LASSO regression was used for feature selection. Based on the selected features, six machine learning prediction models were constructed: Logistic Regression, Random Forest, XGBoost, Gradient Boosting Machine, Elastic Net, and Support Vector Machine. The performance of the models was comprehensively evaluated using the area under the curve (AUC), integrated calibration index (ICI), precision-recall curve (PR), and decision curve analysis (DCA). Feature importance was ranked and explained using SHAP values.</p><p><strong>Results: </strong>Among the 434 patients, 156 individuals (35.9%) were diagnosed with grade ≥ 3 VUR. Seven predictive features were identified: delayed treatment response, annual UTI episodes, hydronephrosis, abnormal renal signal on MRU, febrile UTI (fUTI)/UTI ratio, age at first UTI, and non-Escherichia coli UTI episodes. Discrimination performance was comparable across the six models (test AUC range: 0.810-0.832; all pairwise DeLong tests <i>p</i> > 0.05); XGBoost was selected as the final model based on its good calibration (ICI=0.074) and consistent clinical net benefit, achieving a test AUC of 0.832 (95% CI: 0.757-0.897). Decision curve analysis showed that the model provided net benefits across threshold probabilities ranging from 0.15 to 0.90.</p><p><strong>Conclusions: </strong>We developed and validated a prediction model based on XGBoost, which can be used to assess the risk of high-grade vesicoureteral reflux in children with urinary tract infections. This model has good discrimination, acceptable calibration, and considerable clinical application potential. Additionally, based on this model, we developed and deployed a free online calculator at https://vur-prediction.yezhiqiu.cn, which can assist in real-time individualized risk assessment.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"13 ","pages":"1864622"},"PeriodicalIF":3.6000,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13672018/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2026.1864622","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: High-grade vesicoureteral reflux (VUR) is prone to causing adverse clinical outcomes such as kidney damage, recurrent urinary tract infections, and hypertension. Early identification of the risk of developing high-grade VUR in children with urinary tract infections is of great significance for reducing unnecessary voiding cystourethrography (VCUG), guiding clinical decisions, and optimizing antibiotic management strategies.
Methods: A total of 434 children with urinary tract infections who completed VCUG examination were retrospectively enrolled in this study. They were randomly divided into a training set (n = 304) and a test set (n = 130) in a 7:3 ratio. LASSO regression was used for feature selection. Based on the selected features, six machine learning prediction models were constructed: Logistic Regression, Random Forest, XGBoost, Gradient Boosting Machine, Elastic Net, and Support Vector Machine. The performance of the models was comprehensively evaluated using the area under the curve (AUC), integrated calibration index (ICI), precision-recall curve (PR), and decision curve analysis (DCA). Feature importance was ranked and explained using SHAP values.
Results: Among the 434 patients, 156 individuals (35.9%) were diagnosed with grade ≥ 3 VUR. Seven predictive features were identified: delayed treatment response, annual UTI episodes, hydronephrosis, abnormal renal signal on MRU, febrile UTI (fUTI)/UTI ratio, age at first UTI, and non-Escherichia coli UTI episodes. Discrimination performance was comparable across the six models (test AUC range: 0.810-0.832; all pairwise DeLong tests p > 0.05); XGBoost was selected as the final model based on its good calibration (ICI=0.074) and consistent clinical net benefit, achieving a test AUC of 0.832 (95% CI: 0.757-0.897). Decision curve analysis showed that the model provided net benefits across threshold probabilities ranging from 0.15 to 0.90.
Conclusions: We developed and validated a prediction model based on XGBoost, which can be used to assess the risk of high-grade vesicoureteral reflux in children with urinary tract infections. This model has good discrimination, acceptable calibration, and considerable clinical application potential. Additionally, based on this model, we developed and deployed a free online calculator at https://vur-prediction.yezhiqiu.cn, which can assist in real-time individualized risk assessment.
期刊介绍:
Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate
- the use of patient-reported outcomes under real world conditions
- the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines
- the scientific bases for guidelines and decisions from regulatory authorities
- access to medicinal products and medical devices worldwide
- addressing the grand health challenges around the world